Company news

Zentalis Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

August 8, 2023

Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer

July 31, 2023

Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

June 14, 2023

Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

June 5, 2023

Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting

May 24, 2023

Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations

May 22, 2023

Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

May 9, 2023

Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting

April 25, 2023

Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023

April 16, 2023

Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates

February 28, 2023

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer

February 12, 2023

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

January 31, 2023

Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates

November 8, 2022

Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference

November 7, 2022

Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer

October 23, 2022

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

October 16, 2022

Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer

September 26, 2022

Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer

September 18, 2022

Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors

September 11, 2022

Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

August 8, 2022

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference

August 2, 2022

Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2022

Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary

June 26, 2022

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

May 30, 2022

Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock

May 17, 2022

Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer

May 15, 2022

Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

May 4, 2022

Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer

April 26, 2022

Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR

April 10, 2022

Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR

April 7, 2022

Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3

March 28, 2022

Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis

March 21, 2022

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

February 23, 2022

Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021

December 1, 2021

Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma

November 16, 2021

Zentalis Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

November 9, 2021

Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma

September 12, 2021

Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3

August 31, 2021

Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

August 11, 2021

Zentera Therapeutics Announces Closing of $75 Million Series B Financing

August 1, 2021

Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma

August 1, 2021

Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 30, 2021

Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated

June 27, 2021

Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock

June 27, 2021

Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock

June 27, 2021

Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

May 16, 2021

Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor

April 11, 2021

Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors

April 9, 2021

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

March 24, 2021

Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021

March 9, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 23 decks. Every deck is listed under its year.